These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21785912)

  • 1. Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs).
    Mitchell J; Bauer R; Lyapustina S; Tougas T; Glaab V
    AAPS PharmSciTech; 2011 Sep; 12(3):965-88. PubMed ID: 21785912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particle Size Measurements from Orally Inhaled and Nasal Drug Products.
    Mitchell JP
    J Aerosol Med Pulm Drug Deliv; 2021 Dec; 34(6):325-345. PubMed ID: 34860563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol.
    David Christopher J; Patel RB; Mitchell JP; Tougas TP; Goodey AP; Quiroz J; Andersson PU; Lyapustina S
    AAPS PharmSciTech; 2017 Nov; 18(8):3296-3306. PubMed ID: 28589305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence.
    Christopher D; Adams W; Amann A; Bertha C; Byron PR; Doub W; Dunbar C; Hauck W; Lyapustina S; Mitchell J; Morgan B; Nichols S; Pan Z; Singh GJ; Tougas T; Tsong Y; Wolff R; Wyka B
    AAPS PharmSciTech; 2007 Nov; 8(4):E90. PubMed ID: 18181550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multi-laboratory in Vitro Study to Compare Data from Abbreviated and Pharmacopeial Impactor Measurements for Orally Inhaled Products: a Report of the European Aerosol Group (EPAG).
    Nichols SC; Mitchell JP; Sandell D; Andersson PU; Fischer M; Howald M; Pengilley R; Krüger P
    AAPS PharmSciTech; 2016 Dec; 17(6):1383-1392. PubMed ID: 26762338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).
    Doub W; Stein S; Mitchell J; Goodey AP
    AAPS PharmSciTech; 2020 Aug; 21(7):239. PubMed ID: 32827121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.
    Mitchell JP; Nagel MW; Avvakoumova V; MacKay H; Ali R
    AAPS PharmSciTech; 2009; 10(1):243-51. PubMed ID: 19280348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols.
    Roberts DL; Mitchell JP
    AAPS PharmSciTech; 2013 Jun; 14(2):497-510. PubMed ID: 23508617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two approaches for treating cascade impaction mass balance measurements.
    Wyka B; Tougas T; Mitchell J; Strickland H; Christopher D; Lyapustina S
    J Aerosol Med; 2007; 20(3):236-56. PubMed ID: 17894532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.
    Mitchell JP; Nagel MW; Doyle CC; Ali RS; Avvakoumova VI; Christopher JD; Quiroz J; Strickland H; Tougas T; Lyapustina S
    AAPS PharmSciTech; 2010 Jun; 11(2):843-51. PubMed ID: 20480271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raman chemical imaging for ingredient-specific particle size characterization of aqueous suspension nasal spray formulations: a progress report.
    Doub WH; Adams WP; Spencer JA; Buhse LF; Nelson MP; Treado PJ
    Pharm Res; 2007 May; 24(5):934-45. PubMed ID: 17372686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.
    Mitchell J; Newman S; Chan HK
    AAPS PharmSciTech; 2007 Dec; 8(4):E110. PubMed ID: 18181531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimizing variability of cascade impaction measurements in inhalers and nebulizers.
    Bonam M; Christopher D; Cipolla D; Donovan B; Goodwin D; Holmes S; Lyapustina S; Mitchell J; Nichols S; Pettersson G; Quale C; Rao N; Singh D; Tougas T; Van Oort M; Walther B; Wyka B
    AAPS PharmSciTech; 2008; 9(2):404-13. PubMed ID: 18431675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of Aerodynamic Particle Size Distribution of Orally Inhaled Products by Cascade Impactor: How to Let the Product Specification Drive the Quality Requirements of the Cascade Impactor.
    Roberts DL; Mitchell JP
    AAPS PharmSciTech; 2019 Jan; 20(2):57. PubMed ID: 30623259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).
    Tougas TP; Christopher D; Mitchell JP; Strickland H; Wyka B; Van Oort M; Lyapustina S
    AAPS PharmSciTech; 2009; 10(4):1276-85. PubMed ID: 19882251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
    Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
    AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of the Performance of Efficient Data Analysis Versus Fine Particle Dose as Metrics for the Quality Control of Aerodynamic Particle Size Distributions of Orally Inhaled Pharmaceuticals.
    Tougas TP; Goodey AP; Hardwell G; Mitchell J; Lyapustina S
    AAPS PharmSciTech; 2017 Feb; 18(2):451-461. PubMed ID: 27068528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 2--investigation of bias in extra-fine mass fraction with AIM-HRT impactor.
    Mitchell JP; Nagel MW; Doyle CC; Ali RS; Avvakoumova VI; Christopher JD; Quiroz J; Strickland H; Tougas T; Lyapustina S
    AAPS PharmSciTech; 2010 Sep; 11(3):1115-8. PubMed ID: 20623212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.
    Mitchell JP; Nagel MW; Avvakoumova V; MacKay H; Ali R
    AAPS PharmSciTech; 2009; 10(1):252-7. PubMed ID: 19291411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.